{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:41:46Z","timestamp":1785462106277,"version":"3.56.0"},"reference-count":70,"publisher":"Akademiai Kiado Zrt.","issue":"33","license":[{"start":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T00:00:00Z","timestamp":1692489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,8,20]]},"abstract":"<jats:p>A hypophysis adenil\u00e1t-cikl\u00e1z-aktiv\u00e1l\u00f3 polipeptidet (PACAP) birkahypothalamusb\u00f3l\n                    izol\u00e1lt\u00e1k \u00e9s karakteriz\u00e1lt\u00e1k. Le\u00edrt\u00e1k aminosav-szekvenci\u00e1j\u00e1t, g\u00e9nj\u00e9t,\n                    receptorait, azok g\u00e9nj\u00e9t \u00e9s a szervezetben t\u00f6rt\u00e9n\u0151 el\u0151fordul\u00e1s\u00e1t. A PACAP a\n                    szekretin peptidcsal\u00e1d tagja. Legk\u00f6zelebbi rokona a vazoakt\u00edv intestinalis\n                    polipeptid (VIP). Sz\u00e9les k\u00f6r\u0171 el\u0151fordul\u00e1sa arra utal, hogy a peptidcsal\u00e1d m\u00e1s\n                    tagjaihoz hasonl\u00f3an jelent\u0151s szerepet j\u00e1tszik \u00e9lettani folyamatokban.\n                    \u00c1llatmodelleken v\u00e9gzett k\u00eds\u00e9rletek seg\u00edts\u00e9g\u00e9vel vil\u00e1gszerte intenz\u00edven kutatj\u00e1k\n                    a PACAP szerep\u00e9t k\u00fcl\u00f6nb\u00f6z\u0151 betegs\u00e9gek lehets\u00e9ges kezel\u00e9s\u00e9ben. Az \u00f6sszefoglal\u00f3\n                    munka els\u0151 r\u00e9sze tartalmazza a legfontosabb k\u00eds\u00e9rleti adatokat a peptid \u00e9s\n                    receptor\u00e1nak szerkezet\u00e9re, g\u00e9nj\u00e9re \u00e9s eml\u0151sszervezetben t\u00f6rt\u00e9n\u0151 el\u0151fordul\u00e1s\u00e1ra\n                    vonatkoz\u00f3an. A m\u00e1sodik r\u00e9szben els\u0151sorban a hum\u00e1n anyagon v\u00e9gzett legfontosabb\n                    vizsg\u00e1latokat tekintett\u00fck \u00e1t szervrendszerek szerint. Azokat az eredm\u00e9nyeket\n                    gy\u0171jt\u00f6tt\u00fck \u00f6ssze, amelyek alapj\u00e1n a j\u00f6v\u0151ben es\u00e9ly lehet arra, hogy a PACAP\n                    ter\u00e1pi\u00e1s c\u00e9lra haszn\u00e1lhat\u00f3 legyen. A k\u00e9s\u0151bbiekben felmer\u00fcl annak lehet\u0151s\u00e9ge,\n                    hogy a PACAP v\u00e9rben m\u00e9rt koncentr\u00e1ci\u00f3j\u00e1nak meghat\u00e1roz\u00e1sa a klinikai diagn\u00f3zis, a\n                    differenci\u00e1ldiagn\u00f3zis fel\u00e1ll\u00edt\u00e1s\u00e1ban seg\u00edts\u00e9get ny\u00fajthat. A j\u00f6v\u0151ben lehet\u0151s\u00e9g\n                    ny\u00edlhat PACAP-receptort kifejez\u0151 daganatok nem invaz\u00edv ter\u00e1pi\u00e1j\u00e1ra. A PACAP\n                    r\u00e9szt vesz a hypophysis el\u00fcls\u0151 lebenye m\u0171k\u00f6d\u00e9s\u00e9nek, a vazopresszin-kidob\u00e1snak,\n                    az adrenalinszekr\u00e9ci\u00f3nak, az inzulinszekr\u00e9ci\u00f3nak a szab\u00e1lyoz\u00e1s\u00e1ban,\n                    simaizom-relax\u00e1ns, immunszuppresszor. Az idegrendszerben neurotranszmitter,\n                    neuroprotekt\u00edv agyi ischaemi\u00e1ban, Parkinson-k\u00f3rban, Huntington-chore\u00e1ban,\n                    Alzheimer-betegs\u00e9gben \u00e9s a k\u00f6zponti idegrendszer traum\u00e1s s\u00e9r\u00fcl\u00e9se eset\u00e9n. A\n                    PACAP g\u00e1tolja az apopt\u00f3zist, v\u00e9d\u0151 hat\u00e1s\u00fa oxidat\u00edv stresszben, g\u00e1tolja a\n                    proinflammati\u00f3s, de serkenti az antiinflammati\u00f3s faktorok k\u00e9pz\u0151d\u00e9s\u00e9t. A PACAP\n                    stimul\u00e1lja a daganatos sejtek fejl\u0151d\u00e9s\u00e9t, \u00e9s citoprotekt\u00edv a perif\u00e9ri\u00e1s\n                    szervekben is. R\u00e9szt vesz az \u00e9lettani m\u0171k\u00f6d\u00e9sek napi ritmus\u00e1nak szab\u00e1lyoz\u00e1s\u00e1ban.\n                    Orv Hetil. 2023; 164(33): 1300\u20131310.<\/jats:p>","DOI":"10.1556\/650.2023.32833","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T09:03:14Z","timestamp":1692608594000},"page":"1300-1310","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":5,"title":["Az adenil\u00e1t-cikl\u00e1z-aktiv\u00e1l\u00f3 polipeptid (PACAP) klinikai jelent\u0151s\u00e9ge"],"prefix":"10.1556","volume":"164","author":[{"given":"Andrea","family":"Heinzlmann","sequence":"first","affiliation":[{"name":"\u00c1llatorvostudom\u00e1nyi Egyetem, Anat\u00f3miai \u00e9s Sz\u00f6vettani Tansz\u00e9k Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"K\u00f6ves","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Anat\u00f3miai, Sz\u00f6vet- \u00e9s Fejl\u0151d\u00e9stani Int\u00e9zet Budapest, T\u0171zolt\u00f3 u. 58., 1094 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","article-title":"Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells","volume":"164","author":"Miyata","year":"1989","unstructured":"1. Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989; 164: 567-574.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0167-4781(92)90488-l","article-title":"Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene","volume":"1129","author":"Hosoya","year":"1992","unstructured":"2. Hosoya M, Kimura C, Ogi K, et al. Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochem Biophys Acta 1992; 1129: 199-206.","journal-title":"Biochem Biophys Acta"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.1073\/pnas.90.13.6345","article-title":"Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor","volume":"90","author":"JR","year":"1993","unstructured":"3. Pisegna JR, Wank SA. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA 1993; 90: 6345-6349.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.bbamcr.2012.02.001","article-title":"Receptor-independent cellular uptake of pituitary adenylate cyclase activating polypeptide","volume":"1823","author":"Doan","year":"2012","unstructured":"4. Doan ND, Chatenet D, L\u00e9tourneau M, et al. Receptor-independent cellular uptake of pituitary adenylate cyclase activating polypeptide. Biochim Biophys Acta 2012; 1823: 940-949.","journal-title":"Biochim Biophys Acta"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0196-9781(91)90018-K","article-title":"Immunohistochemical localization of the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACAP), in human and primate hypothalamus","volume":"12","author":"V\u00edgh","year":"1991","unstructured":"5. V\u00edgh S, Arimura A, K\u00f6ves K, et al. Immunohistochemical localization of the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACAP), in human and primate hypothalamus. Peptides 1991; 12: 313-318.","journal-title":"Peptides"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000125864","article-title":"Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain","volume":"54","author":"K\u00f6ves","year":"1991","unstructured":"6. K\u00f6ves K, Arimura A, G\u00f6rcs TG, et al. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. Neuroendocrinology 1991; 54: 159-169.","journal-title":"Neuroendocrinology"},{"key":"ref6","unstructured":"7. Kausz M, Murai Z, Arimura A, et al. Distribution of pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactive elements in the brain stem of rats studied by immunohistochemistry. Neurobiology 1999; 7: 19-31."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0006-8993(95)00869-R","article-title":"Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei","volume":"699","author":"Palkovits","year":"1995","unstructured":"8. Palkovits M, Somogyv\u00e1ri-Vigh A, Arimura A. Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res. 1995; 699: 116-120.","journal-title":"Brain Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1167\/iovs.04-0313","article-title":"Melanopsin is expressed in PACAP-containing retinal ganglion cells of the human retinohypothalamic tract","volume":"45","author":"Hannibal","year":"2004","unstructured":"9. Hannibal J, Hindersson P, \u00d8stergaard J, et al. Melanopsin is expressed in PACAP-containing retinal ganglion cells of the human retinohypothalamic tract. Invest Ophthalmol Vis Sci. 2004; 45: 4202-4209.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0306-4522(93)90018-B","article-title":"Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence","volume":"57","author":"Moller","year":"1993","unstructured":"10. Moller K, Zhang YZ, H\u00e5kanson R, et al. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 1993; 57: 725-732.","journal-title":"Neuroscience"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0306-4522(92)90064-9","article-title":"Pituitary adenylate cyclase activating peptide: a novel vasoactive intestinal peptide-like neuropeptide in the gut","volume":"46","author":"Sundler","year":"1992","unstructured":"11. Sundler F, Ekblad E, Absood A, et al. Pituitary adenylate cyclase activating peptide: a novel vasoactive intestinal peptide-like neuropeptide in the gut. Neuroscience 1992; 46: 439-454.","journal-title":"Neuroscience"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0196-9781(98)00049-7","article-title":"PACAP colocalizes with luteinizing and follicle-stimulating hormone immunoreactivities in the anterior lobe of the pituitary gland","volume":"19","author":"K\u00f6ves","year":"1998","unstructured":"12. K\u00f6ves K, K\u00e1ntor O, Scammel JG, et al. PACAP colocalizes with luteinizing and follicle-stimulating hormone immunoreactivities in the anterior lobe of the pituitary gland. Peptides 1998; 19: 1069-1072.","journal-title":"Peptides"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0167-0115(02)00295-1","article-title":"Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets","volume":"113","author":"Portela-Gomes","year":"2003","unstructured":"13. Portela-Gomes GM, Lukinius A, Ljungberg O, et al. PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. Regul Pept. 2003; 113: 31-39.","journal-title":"Regul Pept"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/and.12102","article-title":"Distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) in the human testis and in testicular germ cell tumors","volume":"46","author":"Nakamura","year":"2013","unstructured":"14. Nakamura K, Nakamachi T, Endo K, et al. Distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) in the human testis and in testicular germ cell tumors. Andrologia 2013; 46: 465-471.","journal-title":"Andrologia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1210\/jc.2007-2621","article-title":"Characterization, expression, and functional activity of pituitary adenylate cyclase-activating polypeptide and its receptors in human granulosa-luteal cells","volume":"93","author":"Morelli","year":"2008","unstructured":"15. Morelli MB, Barberi M, Gambardella A, et al. Characterization, expression, and functional activity of pituitary adenylate cyclase-activating polypeptide and its receptors in human granulosa-luteal cells. J Clin Endocrinol Met. 2008; 93: 4924-4932.","journal-title":"J Clin Endocrinol Met"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1210\/endo.141.3.7346","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta","volume":"141","author":"Scaldaferri","year":"2000","unstructured":"16. Scaldaferri ML, Modesti A, Palumbo C, et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta. Endocrinology 2000; 141: 1158-1167.","journal-title":"Endocrinology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0196-9781(99)00084-4","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP) is present in human and cat gastric glands","volume":"20","author":"Vincze","year":"1999","unstructured":"17. Vincze E, K\u00e1ntor O, Kiss A, et al. Pituitary adenylate cyclase activating polypeptide (PACAP) is present in human and cat gastric glands. Peptides 1999; 20: 937-941.","journal-title":"Peptides"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nbd.2017.04.002","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 (PAC1) in the human infant brain and changes in the sudden infant death syndrome (SIDS)","volume":"103","author":"Huang","year":"2017","unstructured":"18. Huang J, Waters KA, Machaalani R. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 (PAC1) in the human infant brain and changes in the sudden infant death syndrome (SIDS). Neurobiol Dis. 2017; 103: 70-77.","journal-title":"Neurobiol Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00001756-200203250-00030","article-title":"Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia","volume":"13","author":"Knutsson","year":"2002","unstructured":"19. Knutsson M, Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 2002; 13: 507-509.","journal-title":"Neuroreport"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.regpep.2004.05.011","article-title":"Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis","volume":"123","author":"Isobe","year":"2004","unstructured":"20. Isobe K, Kaneko M, Kaneko S, et al. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis. Regul Pep. 2004; 123: 29-32.","journal-title":"Regul Pep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1007\/s12031-022-01985-0","article-title":"Distribution of PACAP and PAC1 receptor in the human eye","volume":"72","author":"Patk\u00f3","year":"2022","unstructured":"21. Patk\u00f3 E, Szab\u00f3 E, T\u00f3th D, et al. Distribution of PACAP and PAC1 receptor in the human eye. J Mol Neurosci. 2022; 72: 2176-2187.","journal-title":"J Mol Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb06946.x","article-title":"In vitro evaluation of VIP\/PACAP receptors in healthy and diseased human tissues: clinical implications","volume":"921","author":"Reubi","year":"2000","unstructured":"22. Reubi JC. In vitro evaluation of VIP\/PACAP receptors in healthy and diseased human tissues: clinical implications. Ann NY Acad Sci USA 2000; 921: 1-25.","journal-title":"Ann NY Acad Sci USA"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s10989-021-10204-0","article-title":"PACAP and PAC1 receptor expression in human insulinomas","volume":"27","author":"Ferencz","year":"2021","unstructured":"23. Ferencz S, T\u00f3th D, Kasz\u00e1s B, et al. PACAP and PAC1 receptor expression in human insulinomas. Int J Peptide Res Therap. 2021; 27: 1719-1728.","journal-title":"Int J Peptide Res Therap"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.3390\/ijms23073715","article-title":"PACAP-38 and PAC1 receptor alterations in plasma and cardiac tissue samples of heart failure patients","volume":"23","author":"Szab\u00f3","year":"2022","unstructured":"24. Szab\u00f3 D, S\u00e1rszegi Zs, Polg\u00e1r B, et al. PACAP-38 and PAC1 receptor alterations in plasma and cardiac tissue samples of heart failure patients. Int J Mol Sci. 2022; 23: 3715.","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0167-0115(02)00108-8","article-title":"Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues","volume":"110","author":"Garc\u00eda-Fern\u00e1ndez","year":"2002","unstructured":"25. Garc\u00eda-Fern\u00e1ndez MO, Bodega G, Solano RM, et al. Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues. Regul Pept. 2002; 110: 9-15.","journal-title":"Regul Pept"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8235","DOI":"10.1158\/1078-0432.CCR-04-0939","article-title":"Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies","volume":"10","author":"Schulz","year":"2004","unstructured":"26. Schulz S, R\u00f6cken C, Mawrin C, et al. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res. 2004; 10: 8235-8242.","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0196-9781(99)00202-8","article-title":"Immunohistochemical localization and distribution of VIP\/PACAP receptors in human lung","volume":"21","author":"Busto","year":"2000","unstructured":"27. Busto R, Prieto JC, Bodega G, et al. Immunohistochemical localization and distribution of VIP\/PACAP receptors in human lung. Peptides 2000; 21: 265-269.","journal-title":"Peptides"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/01.STR.31.6.1411","article-title":"Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat","volume":"31","author":"Regl\u0151di","year":"2000","unstructured":"28. Regl\u0151di D, Somogyv\u00e1ri-V\u00edgh A, V\u00edgh S, et al. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000; 31: 1411-1417.","journal-title":"Stroke"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2174\/138161211795589355","article-title":"Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo","volume":"17","author":"Regl\u0151di","year":"2011","unstructured":"29. Regl\u0151di D, Kiss P, Lubics A, et al. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des. 2011; 17: 962-972.","journal-title":"Curr Pharm Des"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s11357-022-00530-6","article-title":"Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson's disease focusing on correlations with motor symptoms","volume":"44","author":"Pham","year":"2022","unstructured":"30. Pham D, Polg\u00e1r B, T\u00f3th T, et al. Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson's disease focusing on correlations with motor symptoms. GeroScience 2022; 44: 785-803.","journal-title":"GeroScience"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. De Souza FR, Ribeiro FM, d'Almeida Lima PM. Implications of VIP and PACAP in Parkinson's disease: what do we know so far? Curr Med Chem. 2021; 28: 1703-1715.","DOI":"10.2174\/0929867327666200320162436"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12640-017-9841-7","article-title":"Alteration of the PAC1 receptor expression in the basal ganglia of MPTP-induced Parkinsonian macaque monkeys","volume":"33","author":"Feh\u00e9r","year":"2018","unstructured":"32. Feh\u00e9r M, Gaszner B, Tam\u00e1s A, et al. Alteration of the PAC1 receptor expression in the basal ganglia of MPTP-induced Parkinsonian macaque monkeys. Neurotox Res. 2018; 33: 702-715.","journal-title":"Neurotox Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1212\/WNL.0000000000000417","article-title":"Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease","volume":"82","author":"Han","year":"2014","unstructured":"33. Han P, Liang W, Baxter LC, et al. Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease. Neurology 2014; 82: 1724-1728.","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1469-7793.1997.319bb.x","article-title":"Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats","volume":"505","author":"Yada","year":"1997","unstructured":"34. Yada T, Sakurada M, Ishihara H, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J Physiol. 1997; 505: 319-328.","journal-title":"J Physiol"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Sanlioglu AD, Karacay B, Balci MK, et al. Therapeutic potential of VIP vs PACAP in diabetes. J Mol Endocrin. 2012; 49: R157-R167.","DOI":"10.1530\/JME-12-0156"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1097\/00001756-199507310-00006","article-title":"Effects of intravenously infused pituitary adenylate cyclase activating polypeptide on arginine vasopressin and oxytocin secretion in man","volume":"6","author":"Chiodera","year":"1995","unstructured":"36. Chiodera P, Volpi R, Capretti L, et al. Effects of intravenously infused pituitary adenylate cyclase activating polypeptide on arginine vasopressin and oxytocin secretion in man. Neuroreport 1995; 6: 1490-1492.","journal-title":"Neuroreport"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1749-6632.2000.tb06971.x","article-title":"Role of PACAP1 receptor in regulation of ECL cells and gastric acid secretion by pituitary adenylate cyclase activating peptide","volume":"921","author":"Pisegna","year":"2000","unstructured":"37. Pisegna JR, Ohning GV, Athmann C, et al. Role of PACAP1 receptor in regulation of ECL cells and gastric acid secretion by pituitary adenylate cyclase activating peptide. Ann N Y Acad Sci. 2000; 921: 233-241.","journal-title":"Ann N Y Acad Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1111\/jcmm.14453","article-title":"PACAP ameliorates hepatic metabolism and inflammation through up\u2010regulating FAIM in obesity","volume":"23","author":"Xiao","year":"2019","unstructured":"38. Xiao X, Qiu P, Gong HZ, et al. PACAP ameliorates hepatic metabolism and inflammation through up\u2010regulating FAIM in obesity. J Cell Mol Med. 2019; 23: 5970-5980.","journal-title":"J Cell Mol Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1164\/rccm.201210-1789OC","article-title":"ADCYAP1R1 and asthma in Puerto Rican children","volume":"187","author":"Chen","year":"2013","unstructured":"39. Chen W, Boutaoui N, Brehm JM, et al. ADCYAP1R1 and asthma in Puerto Rican children. Am J Respir Crit Care Med. 2013; 187: 584-588.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0167-0115(93)90426-9","article-title":"Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the cardiovascular system","volume":"47","author":"Suzuki","year":"1993","unstructured":"40. Suzuki Y, Kasai K, Takekoshi K, et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the cardiovascular system. Regul Pep. 1993; 47: 213-220.","journal-title":"Regul Pep"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000065535","article-title":"An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog","volume":"66","author":"Markos","year":"2002","unstructured":"41. Markos F, Hennessy BA, Fitzpatrick M, et al. An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog. Pharmacology 2002; 66: 206-210.","journal-title":"Pharmacology"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Farnham MM, Inglott MA, Pilowsky PM. Intrathecal PACAP-38 causes increases in sympathetic nerve activity and heart rate but not blood pressure in the spontaneously hypertensive rat. Am J Physiol. 2011; 300: H214-H222.","DOI":"10.1152\/ajpheart.00662.2010"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1161\/01.CIR.0000147235.53360.59","article-title":"Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type 1 receptor-deficient mice","volume":"110","author":"Otto","year":"2004","unstructured":"43. Otto C, Hein L, Brede M, et al. Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type 1 receptor-deficient mice. Circulation 2004; 110: 3245-3251.","journal-title":"Circulation"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12031-017-1025-7","article-title":"Examination of pituitary adenylate cyclase-activating polypeptide (PACAP) as a potential biomarker in heart failure patients","volume":"68","author":"S\u00e1rszegi","year":"2019","unstructured":"44. S\u00e1rszegi Z, Szab\u00f3 D, Gaszner B, et al. Examination of pituitary adenylate cyclase-activating polypeptide (PACAP) as a potential biomarker in heart failure patients. J Mol Neurosci. 2019; 68: 368-376.","journal-title":"J Mol Neurosci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s12031-012-9743-3","article-title":"Correlation between oocyte number and follicular fluid concentration of pituitary adenylate cyclase-activating polypeptide (PACAP) in women after superovulation treatment","volume":"48","author":"Kopp\u00e1n","year":"2012","unstructured":"45. Kopp\u00e1n M, V\u00e1rnagy A, Regl\u0151di D, et al. Correlation between oocyte number and follicular fluid concentration of pituitary adenylate cyclase-activating polypeptide (PACAP) in women after superovulation treatment. J Mol Neurosci. 2012; 48: 617-622.","journal-title":"J Mol Neurosci"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. Regl\u0151di D, Helyes Zs, N\u00e9meth J, et al. PACAP as a potential biomarker: alterations of PACAP levels in human physiological and pathological conditions. In: Regl\u0151di D, Tam\u00e1s A. (eds.) Pituitary adenylate cyclase activating polypeptide - PACAP. Current topics in neurotoxicity (11). Springer, Cham, 2016; pp. 815-832.","DOI":"10.1007\/978-3-319-35135-3_48"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. Dow RC, Bennie J, Fink G. Pituitary adenylate cyclase activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol. 1994; 142: R1-R4.","DOI":"10.1677\/joe.0.142R001"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.regpep.2007.09.012","article-title":"Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases","volume":"145","author":"Li","year":"2008","unstructured":"48. Li M, Maderdrut JL, Lertora JJ, et al. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. Regul Pept. 2008; 145: 24-32.","journal-title":"Regul Pept"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s000110050363","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells","volume":"47","author":"\u00d8dum","year":"1998","unstructured":"49. \u00d8dum L, Petersen LJ, Skov PS, et al. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res. 1998; 47: 488-492.","journal-title":"Inflamm Res"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50. Horv\u00e1th G, N\u00e9meth J, Brubel R, et al. Occurrence and functions of PACAP in the placenta. In: Regl\u0151di D, Tam\u00e1s A. (eds.) Pituitary adenylate cyclase activating polypeptide - PACAP. Current topics in neurotoxicity (11). Springer, Cham, 2016; pp. 389-403.","DOI":"10.1007\/978-3-319-35135-3_23"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51. Ressler KJ, Mercer KB, Bradley B, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 2011; 470: 492-497. Erratum: Nature 2011; 477: 120.","DOI":"10.1038\/nature09856"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2007-06-098558","article-title":"PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications","volume":"111","author":"Freson","year":"2008","unstructured":"52. Freson K, Peeters K, De Vos R, et al. PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications. Blood 2008; 111: 1885-1893.","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"53. Di Michele M, Peeters K, Loyen S, et al. Pituitary adenylate cyclase activating polypeptide (PACAP) impairs the regulation of apoptosis in megakaryocytes by activating NF-\u03baB: a proteomic study. Mol Cell Proteomics 2012; 11: M111.","DOI":"10.1074\/mcp.M111.007625"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54. Tam\u00e1s A, Vass RA, Helyes Zs, et al. Examination of PACAP during lactation. In: Regl\u0151di D, Tam\u00e1s A. (eds.) Pituitary adenylate cyclase activating polypeptide - PACAP. Current topics in neurotoxicity (11). Springer, Cham, 2016; pp. 833-840.","DOI":"10.1007\/978-3-319-35135-3_49"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1556\/APhysiol.100.2013.1.2","article-title":"Examination of PACAP38-like immunoreactivity in different milk and infant formula samples","volume":"100","author":"Csanaky","year":"2013","unstructured":"55. Csanaky K, Regl\u0151di D, B\u00e1nki E, et al. Examination of PACAP38-like immunoreactivity in different milk and infant formula samples. Acta Physiol Hung. 2013; 100: 28-36.","journal-title":"Acta Physiol Hung"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56. Delgado M. Immunobiology of the pituitary adenylate cyclase-activating peptide. In: Regl\u0151di D, Tam\u00e1s A. (eds.) Pituitary adenylate cyclase activating polypeptide - PACAP. Current topics in neurotoxicity (11). Springer, Cham, 2016; pp. 691-708.","DOI":"10.1007\/978-3-319-35135-3_40"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.peptides.2007.05.002","article-title":"Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study","volume":"28","author":"Li","year":"2007","unstructured":"57. Li M, Maderdrut JL, Lertora J, et al. Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 2007; 28: 1891-1895.","journal-title":"Peptides"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/0306-4522(93)90019-C","article-title":"Pituitary adenylate cyclase activating peptide produces a marked and long-lasting depression of a C-fibre-evoked flexion reflex","volume":"57","author":"Zhang","year":"1993","unstructured":"58. Zhang YZ, Sj\u00f6lund B, Moller K, et al. Pituitary adenylate cyclase activating peptide produces a marked and long-lasting depression of a C-fibre-evoked flexion reflex. Neuroscience 1993; 57: 733-737.","journal-title":"Neuroscience"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/0333102413483931","article-title":"Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients","volume":"33","author":"Tuka","year":"2013","unstructured":"59. Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013; 33: 1085-1095.","journal-title":"Cephalalgia"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/brain\/awn307","article-title":"PACAP38 induces migraine-like attacks in patients with migraine without aura","volume":"132","author":"Schytz","year":"2009","unstructured":"60. Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009; 132: 16-25.","journal-title":"Brain"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61. Han L, Liu Y, Xiong H, et al. CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta-analysis. Brain Behav. 2019; 9: e01215.","DOI":"10.1002\/brb3.1215"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.0000000000002261","article-title":"Changes in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study","volume":"86","author":"Amin","year":"2016","unstructured":"62. Amin FM, Hougaard A, Magon S, et al. Changes in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study. Neurology 2016; 86: 180-187.","journal-title":"Neurology"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63. Edvinsson L. Pituitary adenylate cyclase activating polypeptide (PACAP) in migraine pathophysiology. In: Regl\u0151di D, Tam\u00e1s A. (eds.) Pituitary adenylate cyclase activating polypeptide - PACAP. Current topics in neurotoxicity (11). Springer, Cham, 2016; pp. 609-615.","DOI":"10.1007\/978-3-319-35135-3_35"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0333102420970889","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention","volume":"41","author":"Ashina","year":"2021","unstructured":"64. Ashina M, Dole\u017eil D, Bonner JH, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 2021; 41: 33-44.","journal-title":"Cephalalgia"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-022-01435-7","article-title":"CGRP and PACAP-38 play an important role in diagnosing pediatric migraine","volume":"23","author":"Liu","year":"2022","unstructured":"65. Liu J, Wang G, Dan Y, et al. CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J Headache Pain 2022; 23: 68.","journal-title":"J Headache Pain"},{"key":"ref65","unstructured":"66. Sipka G, Besenyi Z, Farkas I, et al. Theranostics in 2020: Neuroendocrine tumors. [Teranosztikumok 2020-ban: Neuroendokrin tumorok.] Magy Onkol. 2020; 64: 119-130. [Hungarian]."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1385\/JMN:22:1-2:83","article-title":"Differential coupling of the PAC1 SV1 splice variant on human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2+ does not activate tumor proliferation","volume":"22","author":"Germano","year":"2004","unstructured":"67. Germano PM, Le SV, Oh DS, et al. Differential coupling of the PAC1 SV1 splice variant on human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2+ does not activate tumor proliferation. J Mol Neurosci. 2004; 22: 83-91.","journal-title":"J Mol Neurosci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.peptides.2012.05.021","article-title":"Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins","volume":"36","author":"Nonaka","year":"2012","unstructured":"68. Nonaka N, Farr SA, Nakamachi T, et al. Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins. Peptides 2012; 36: 168-175.","journal-title":"Peptides"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1556\/019.70.2019.08","article-title":"Intranasal application of PACAP and \u03b2-cyclodextrin before the \"critical period of proestrous stage\" can block ovulation","volume":"70","author":"Heinzlmann","year":"2019","unstructured":"69. Heinzlmann A, Ol\u00e1h M, K\u00f6ves K. Intranasal application of PACAP and \u03b2-cyclodextrin before the \"critical period of proestrous stage\" can block ovulation. Biol Futur. 2019; 70: 62-70.","journal-title":"Biol Futur"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"585082","DOI":"10.3389\/fendo.2020.585082","article-title":"Intranasal administration of PACAP is an efficient delivery route to reduce infarct volume and promote functional recovery after transient and permanent middle cerebral artery occlusion","volume":"11","author":"Cherait","year":"2021","unstructured":"70. Cherait A, Maucotel J, Lefranc B, et al. Intranasal administration of PACAP is an efficient delivery route to reduce infarct volume and promote functional recovery after transient and permanent middle cerebral artery occlusion. Front Endocrinol. 2021; 11: 585082.","journal-title":"Front Endocrinol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1300.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1300.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1300.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:46:12Z","timestamp":1697802372000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/33\/article-p1300.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,20]]},"references-count":70,"journal-issue":{"issue":"33"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32833","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,20]]}}}